IMUNON CEO Dr. Corinne Le Goff to Participate in a Panel Discussion on Pandemic Preparedness at the United Nations
2023年10月19日 - 9:30PM
IMUNON, Inc. (NASDAQ: IMNN), a
clinical-stage biotechnology company focused on harnessing the
power of the immune system against cancer and infectious diseases,
announces that Dr. Corinne Le Goff, IMUNON’s President and Chief
Executive Officer, will be participating in a pandemic preparedness
panel at the United Nations in New York City on Thursday, October
19, 2023. Titled “A Tale of Two Pandemics: Lessons from the 1889
& 2019 Pandemics – Insights for Pandemic Preparedness,” the
program is presented by the Foreign Policy Association, WBB
Securities and UNITAR.
Dr. Le Goff will discuss the development of the
Covid-19 mRNA vaccine and IMUNON’s development of a DNA-based
vaccine platform using the company’s PlaCCine modality. The
moderator is Dr. Richard Marfuggi, M.D., D.M.H., Medical Ethicist,
Medical Historian and Medical Director of the WBB Research
Institute. Opening remarks will be delivered by H.E. Bob Rae,
Permanent Representative of the Permanent Mission of Canada to the
United Nations, and by Noel Lateef, Chief Executive Officer and
President of the Foreign Policy Association.
In addition to Dr. Le Goff, the other panelists
include:
- Stijn Van Nieuwerburg, Ph.D.,
Columbia University Graduate School of Business, who will discuss
the realities of commercial real estate including global economic
and social repercussions;
- Alain Gagnon, Ph.D., Professor at
the University of Montreal, who will discuss 1889 effects on 1918
and the implications for 2019 and beyond;
- Gregory Wawro, Ph.D., Professor of
Political Science, Columbia University School of Professional
Studies, who will discuss the political implications of the 1889
and 2019 pandemics; and
- Steve Brozak, D.M.H., Founder &
CEO of WBB Securities, LLC and the WBB Research Institute, who will
discuss the economic consequences of the two pandemics.
Founded in 1918, the mission of the
Foreign Policy Association today, as it has been
throughout its 105-year history, is to serve as a catalyst for
developing awareness, understanding an informed opinion on U.S.
foreign policy and global issues. Through its balanced, nonpartisan
publications and programs, FPA encourages citizens to participate
in the foreign policy process. To learn more about the Foreign
Policy Association, please visit www.fpa.org.
WBB Research Institute’s
mission is to inform the leaders in commerce, industry, government
and public policy about key issues emerging at the intersection of
health care and industry. Its goal is to present and publish
seminars, discussions, articles and studies to better enable
leaders from government, media and other involved interests to both
inform the public and to improve the quality of our lives.
UNITAR’s (United Nations
Institute for Training and Research) mission is to develop the
individual, institutional and organizational capacities of
countries and other United Nations stakeholders through
high-quality learning solutions and related knowledge products and
services to enhance decision making and to support country-level
action for overcoming global challenges.
About IMUNON
IMUNON is a fully integrated, clinical stage
biotechnology company focused on advancing a portfolio of
innovative treatments that harness the body’s natural mechanisms to
generate safe, effective and durable responses across a broad array
of human diseases, constituting a differentiating approach from
conventional therapies. IMUNON is developing its non-viral DNA
technology across four modalities. The first modality, TheraPlas™,
is developed for the coding of proteins and cytokines in the
treatment of solid tumors where an immunological approach is deemed
promising. The second modality, PlaCCine™, is developed for the
coding of viral antigens that can elicit a strong immunological
response. This technology may represent a promising platform for
the development of vaccines in infectious diseases. The third
modality, FixPlas™, concerns the application of our DNA technology
to produce universal cancer vaccines also called tumor associated
antigen cancer vaccines. Finally, the fourth modality, which is
still in the discovery phase, IndiPlas™, will focus on the
development of personalized cancer vaccines, or neoepitope cancer
vaccines.
The Company’s lead clinical program, IMNN-001,
is a DNA-based immunotherapy for the localized treatment of
advanced ovarian cancer currently in Phase 2 development. IMNN-001
works by instructing the body to produce safe and durable levels of
powerful cancer fighting molecules, such as interleukin-12 and
interferon gamma, at the tumor site. Additionally, the Company is
conducting IND-enabling preclinical studies for the development of
a COVID-19 booster vaccine: IMNN-101. The Company has also
initiated preclinical studies to develop a Trp2 tumor associated
antigen cancer vaccine in melanoma: IMNN-201. We will continue to
leverage these modalities and to advance the technological frontier
of plasmid DNA to better serve patients with difficult-to-treat
conditions. For more information on IMUNON,
visit www.imunon.com.
Contacts:
IMUNON |
LHA Investor Relations |
Jeffrey W. Church |
Kim Sutton Golodetz |
Executive Vice President, CFO |
212-838-3777 |
609-482-2455 |
Kgolodetz@lhai.com |
jchurch@imunon.com |
|
# # #
Imunon (NASDAQ:IMNN)
過去 株価チャート
から 4 2024 まで 5 2024
Imunon (NASDAQ:IMNN)
過去 株価チャート
から 5 2023 まで 5 2024